Abstract 145P
Background
Perioperative immunotherapy has become a new standard of care in resectable locally advanced NSCLC. However, the optimal neoadjuvant and adjuvant treatment are unknown. Angiogenesis inhibitors have been reported to adjust tumor microenvironment and synergistic effects of immunotherapy. Here, we present updated efficacy and safety data of Penpulimab-based combination neoadjuvant/adjuvant therapy for this population in ALTER-L043.
Methods
Patients (pts) with resectable stage IIB-IIIB (N2) NSCLC, without driver gene mutations, were randomized 1:1:1 to receive one of the three regimens in 21-day cycle: Penpulimab (200mg, iv, day 1) + chemotherapy + Anlotinib (12mg, po, day 1-14) (Arm A) or Penpulimab (200mg, iv, day 1) + chemotherapy (Arm B) or Penpulimab (200mg, iv, day 1) + Anlotinib (12mg, po, day 1-14) (Arm C) for 3-4 cycles before surgery, followed by adjuvant therapy of Penpulimab + Anlotinib (Arm A, C) or Penpulimab monotherapy (Arm B) for a year at most. Primary endpoint was major pathological response (MPR) rate, secondary endpoints were objective response rate (ORR), pathologic complete response (pCR), event-free survival (EFS), 1 year EFS rate, overall survival (OS) and safety.
Results
A total of 90 pts were randomized to Arm A (n=30) or Arm B (n=30) or Arm C (n=30). At data cutoff on Sep 30, 2024, median follow-up was 12.8 months. Definitive surgery rates in Arm A/B/C were 62.5% vs 89.7% vs 70.0% respectively. The MPR rates of intention to treat (ITT) population were 76.0% vs 57.7% vs 52.4% in the three arms, and 52.0% vs 50.0% vs 38.1% pts showed pCR respectively. ORR of neoadjuvant therapy was 77.8% vs 58.6% vs 63.3% in the three arms. The incidence of grade ≥ 3 adverse events (AEs) were 46.7% vs 36.7% vs 13.3% respectively. There is no fatal AE related to Penpulimab or Anlotinib.
Conclusions
The results demonstrated that these new perioperative combinations of ICI and Anti-angiogenesis agent (Penpulimab and Anlotinib) with or without chemotherapy showed promising efficacy and with manageable safety profiles.
Clinical trial identification
NCT04846634.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
226P - Profiling of gastric adenocarcinomas from EU and LATAM countries identifies distinct tumor immune subgroups and a central role of the tumor microbiome in shaping the immune microenvironment
Presenter: Manuel Cabeza Segura
Session: Poster Display session
Resources:
Abstract
228P - Modulating mitochondrial dynamics in TAMs to enhance anti-tumor immunity
Presenter: Pu-ste Liu
Session: Poster Display session
Resources:
Abstract
229P - Investigation of the effects of long-noncoding RNA NRAV on interferon response in melanoma
Presenter: Kadir Durmus
Session: Poster Display session
Resources:
Abstract
230P - Deciphering the mechanism of immunosuppressive activity of acetaminophen in the context of cancer immunotherapy
Presenter: Jeanne Lena
Session: Poster Display session
Resources:
Abstract
231P - The impact of calcitriol and tacalcitol on the Th17 lymphocytes in breast cancer
Presenter: Beata Filip-Psurska
Session: Poster Display session
Resources:
Abstract